(E)-Rose oxide is a high-impact rosy monoterpene ether best known for giving lift and recognizably rosy character to rose, geranium, and related floral profiles. In the AromaForge archive it is especially relevant in bourbon and Chinese geranium records. The live evidence base is fairly balanced across identity, odor importance, occurrence, metabolism, and fragrance-safety review, with a smaller preclinical pharmacology literature led by anti-inflammatory animal work. That supports positioning rose oxide as a potent floral marker constituent with exploratory bioactivity data, not as a clinically established active.
Chemical identity and composition
PubChem lists rose oxide as CID 27866 with formula C10H18O. The literature often discusses rose oxide as a stereoisomeric set of cis and trans forms, and recent human biomonitoring work notes that natural rose oxide is dominated by the (-)-cis isomer whereas synthetic material contains a different enantiomeric distribution.
Aroma and practical use
- Use the recorded rosy, green, metallic-floral, diffusive, rose-like, fresh, geranium-like, lychee-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2012 Int Immunopharmacol study reported that rose oxide reduced formalin late-phase pain behavior, CFA-induced paw edema, carrageenan edema, MPO activity, and leukocyte migration, while lowering local IL-1beta but not TNF-alpha in tested inflammatory models.
This is the strongest direct constituent pharmacology paper located for rose oxide in this pass.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2015 Biopharm Drug Dispos study found that CYP2B6 and CYP2C19 were the primary recombinant human P450 enzymes catalyzing metabolism of (-)-cis- and (-)-trans-rose oxide, with CYP2B6 appearing especially important in human liver microsomes.
This provides useful metabolism context for exposure and safety framing.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2025 human biomonitoring study reported fast urinary elimination of synthetic rose oxide after controlled oral dosing, with a mean half-life of 4.1 hours and near-complete excretion within 48 hours.
This is unusual among fragrance constituents because it provides direct human toxicokinetic data rather than only animal or in-vitro metabolism evidence.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
A 2017 rose-oil aroma paper identified rose oxide among the very important constituents contributing to the verified aroma profile of rose oil.
This supports strong sensory relevance even when rose oxide is present at low abundance.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedA dedicated RIFM fragrance ingredient safety assessment exists for rose oxide, and an updated assessment was published in 2023.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Recent human biomonitoring work provides direct exposure and toxicokinetic context, but it focused on synthetic rose oxide and biomarker development rather than consumer efficacy.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
No direct public citation is attached to this entry.
This pass did not verify a public aromatherapy-style dermal maximum for isolated rose oxide.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
reduced_il1b_and_leukocyte_migration
The main direct rose-oxide animal paper reported reduced IL-1beta production, lower myeloperoxidase activity, and reduced leukocyte migration in inflammatory models.
This experimental finding does not establish benefit, dose or safety in people using this blend.
cyp2b6_led_human_microsomal_metabolism
Human liver microsome work indicates CYP2B6 is a primary enzyme involved in rose oxide metabolism, with CYP2C19 and isomer-specific CYP1A2 contributions in vitro.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- No public aromatherapy-style dermal limit for isolated rose oxide was verified in this pass.
- Most direct efficacy-style data for rose oxide remain animal or in-vitro rather than clinical.
- Natural rose oxide is stereochemically complex, and many sources discuss mixed rose oxide rather than explicitly isolated (E)-rose oxide.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.